{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Patil A"],"pubmed_abstract":["<h4>Background</h4>We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).<h4>Methods</h4>This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.<h4>Results</h4>COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoi"],"journal":["BMC rheumatology"],"pagination":["32"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9192133"],"repository":["biostudies-literature"],"pubmed_title":["A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases."],"pmcid":["PMC9192133"],"pubmed_authors":["Chandrashekara S","Sangeetha KN","Srinivasa C","Rao VK","Nagaraj S","Chanakya K","Dharmanand BG","Patil A","Daware M","Haridas V","Kumar S","Pinto B","Dharmapalaiah C","Janardana R","Jois R","Singhai S","Subramanian R","Jain V","Shenoy P","Singh YP","Shobha V"],"additional_accession":[]},"is_claimable":false,"name":"A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases.","description":"<h4>Background</h4>We conducted this study to identify the influence of prolonged use of hydroxychloroquine (HCQ), glucocorticoids and other immunosuppressants (IS) on occurrence and outcome of COVID-19 in patients with autoimmune rheumatic diseases (AIRDs).<h4>Methods</h4>This was a prospective, multicenter, non-interventional longitudinal study across 15 specialist rheumatology centers. Consecutive AIRD patients on treatment with immunosuppressants were recruited and followed up longitudinally to assess parameters contributing to development of COVID-19 and its outcome.<h4>Results</h4>COVID-19 occurred in 314 (3.45%) of 9212 AIRD patients during a median follow up of 177 (IQR 129, 219) days. Long term HCQ use had no major impact on the occurrence or the outcome of COVID-19. Glucocorticoi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-04-04T09:27:28.694Z","creation":"2024-10-19T13:26:33.41Z"},"accession":"S-EPMC9192133","cross_references":{"pubmed":["35698182"],"doi":["10.1186/s41927-022-00264-0"]}}